Free Trial

Oppenheimer's Rating of Corbus Pharmaceuticals on 11/11/2026

On November 11, 2026, Oppenheimer updated its outlook on Corbus Pharmaceuticals (NASDAQ:CRBP) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
11/12/2026
Workday, Inc. stock logo
WDAY
Workday
Reiterated Rating
11/12/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Downgrade
11/12/2026
McGrath RentCorp stock logo
MGRC
McGrath RentCorp
Boost Price Target
11/12/2026
AGI Inc stock logo
AGBK
AGI
Lower Price Target
11/11/2026
Kopin Corporation stock logo
KOPN
Kopin
Reiterated Rating
11/11/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Lower Price Target
More Ratings From Oppenheimer Holdings, Inc.